Science is driving combination therapies to overcome resistance and increase effectiveness. That is the future oncology landscape that anyone bringing new products to market needs to be aware of.
Tag Archives | Pharma CI
A modern David versus Goliath story in cancer drug development is unfolding as Clovis Oncology race to market against AstraZeneca; both companies have drugs in early clinical development that appear effective against T790M mutated lung cancer, for which there is currently no approved treatment.
One of the hot topic of conversation amongst the VCs at the JP Morgan Healthcare conference in San Francisco this past week was the field of immuno-oncology. We have already seen significant excitement in anti-PD1/PD-L1 drugs and their early promise in melanoma, renal and lung cancers. Taking a more strategic view, however, the question is how will immuno-oncology change the treatment landscape on a broader scale?
For those on the cancer conference circuit, 2014 is the year of the west coast swing, with 3 major meetings in San Francisco and two in San Diego. Here’s our calendar of key cancer meetings that we plan to attend in person or write about on Biotech Strategy Blog and Pharma Strategy Blog.
The annual Molecular Targets and Cancer Therapeutics meeting returns to Boston later this week and will offer insights into new cancer drugs in development including AZD9291, PF-06463922, CRLX101, BMN 673, ABT-199/GDC-0199.
Next week sees the start of the 2013 European Cancer Congress in Amsterdam. ECCO have announced that King Willem-Alexander of the Netherlands will attend the opening ceremony, which is impressive. Now that most of the meeting abstracts are available online we are starting to focus on what data may be hot at the meeting.
Today, Biotech Strategy Blog launched a paywall where insights from cancer conferences will be available to subscribers who pay a fee for access. It’s the first in a series of online digital and print products that we will be launching in coming months. Sign up if you would like to obtain exclusive insights from 2013 European Cancer Congress, AACR Molecular Targets meeting in Boston and ASH annual meeting in New Orleans.
Tumor Lysis Syndrome (TLS) has been in the news recently as a result of two patient deaths in a chronic lymphocytic leukemia (CLL) clinical trial with AbbVie’s ABT-199, a novel BCL-2 inhibitor in early stages of development. What is TLS and why is this important in cancer research was subsequently analyzed by Icarus Consultants hematology industry expert, Sally Church, PhD on Pharma Strategy Blog.
Data is now commoditized. While obtaining data is relatively easy, insights are a lot more expensive and difficult to generate. Why? They require the application of knowledge, deep understanding and expertise of the topic to analyze, conceptualize and visualize data, and then extrapolate what it means to a company or product. Making sense of data is what we do.
Multiple Myeloma (MM) is forecast to be a hot topic at the forthcoming annual meeting of the American Society of Hematology (ASH) that starts in Atlanta next week. Based on our experience, multiple myeloma is a challenging topic for pharma market research.